SPARC

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE232I01014
  • NSEID: SPARC
  • BSEID: 532872
INR
190.15
-2.5 (-1.3%)
BSENSE

Nov 20

BSE+NSE Vol: 5.06 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Morepen Labs.
Innova Captab
Bliss GVS Pharma
IOL Chemicals
Sanofi India
Strides Pharma
Orchid Pharma
SPARC
P & G Health Ltd
Sanofi Consumer
FDC
Why is Sun Pharma Advanced Research Company Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Low Debt Company with Strong Long Term Fundamental Strength
3
Flat results in Sep 26
  • NET SALES(Q) At Rs 30.03 cr has Fallen at -93.7% (vs previous 4Q average)
  • PBT LESS OI(Q) At Rs -47.93 cr has Fallen at -112.2% (vs previous 4Q average)
  • PAT(Q) At Rs -24.39 cr has Fallen at -106.1% (vs previous 4Q average)
4
Stock is technically in a Mildly Bullish range
  • Multiple factors for the stock are Bullish like Bollinger Band, KST and OBV
5
With ROE of 114.3, it has a Expensive valuation with a 4.3 Price to Book Value
  • Over the past year, while the stock has generated a return of 37.54%, its profits have risen by 717.3% ; the PEG ratio of the company is 0
6
Despite the size of the company, domestic mutual funds hold only 0.28% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
7
Market Beating Performance
  • The stock has generated a return of 37.54% in the last 1 year, much higher than market (BSE500) returns of 0.37%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to SPARC should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is SPARC for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
SPARC
37.54%
0.63
59.81%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
466.97%
EBIT Growth (5y)
142.91%
EBIT to Interest (avg)
-33.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.87
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.85%
ROCE (avg)
36.32%
ROE (avg)
38.10%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
4
Industry P/E
40
Price to Book Value
4.29
EV to EBIT
3.01
EV to EBITDA
2.99
EV to Capital Employed
33.41
EV to Sales
2.53
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
1111.20%
ROE (Latest)
114.29%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
NET SALES(Latest six months)

At Rs 69.95 cr has Grown at 299.71%

PAT(9M)

Higher at Rs 1,716.17 Cr

-11What is not working for the Company
NET SALES(Q)

At Rs 30.03 cr has Fallen at -93.7% (vs previous 4Q average

PBT LESS OI(Q)

At Rs -47.93 cr has Fallen at -112.2% (vs previous 4Q average

PAT(Q)

At Rs -24.39 cr has Fallen at -106.1% (vs previous 4Q average

OPERATING PROFIT TO INTEREST (Q)

Lowest at -380.08 times

Loading Valuation Snapshot...
Here's what is not working for SPARC
Net Sales - Quarterly
At Rs 30.03 cr has Fallen at -93.7% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 477.36 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -47.93 cr has Fallen at -112.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 392.76 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs -24.39 cr has Fallen at -106.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 399.16 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit to Interest - Quarterly
Lowest at -380.08 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest